Early aggressive treatment in patients whose cancer is likely to progress slowly, if at all, causes side-effects and reduces their quality of life for no benefit. Can active surveillance avoid this?
Related Articles
Systems & Services
An important piece of the localised prostate cancer puzzle?
Featured
The do-nothing dilemma
Cutting Edge